Ocelot Bio

Ocelot Bio is a clinical-stage biopharmaceutical company that is dedicated to developing innovative therapeutics aimed at improving outcomes for patients with liver disease, particularly end-stage liver disease (ESLD). The company's lead clinical candidate, OCE-205, is a therapeutic peptide designed to selectively address complications induced by portal hypertension in patients with ESLD, such as hepatorenal syndrome with acute kidney injury (HRS-AKI) and ascites, which could potentially lead to serious and life-threatening outcomes. Ocelot Bio has begun a Phase 2 clinical trial of OCE-205 in HRS-AKI, and the U.S. Food & Drug Administration (FDA) has granted OCE-205 Orphan Drug Designation in the treatment of hepatorenal syndrome. Founded in 2020 by leading experts in therapeutic peptide development, Ocelot Bio has garnered support from a strong syndicate of investors, including Venrock, RA Capital Management, and Vivo Capital. The company's core focus lies in the biotechnology, health care, and life sciences industries, with its headquarters based in the United States. For further details, one can access additional information on the company by visiting www.ocelotbio.com.